📈 Jumpstart Signal Watchlist — August 04, 2026

🏢 What they do: Kenvue Inc. is a global consumer health company that makes and sells everyday health and personal care products. Its brands include Tylenol, Zyrtec, Listerine, Neutrogena, Aveeno, Johnson’s, and BAND-AID, spanning products for self-care, skin health and beauty, and essential health.
- 🎯 Current $19.55 is 22% below 3yr high $25.12 · ⏳ SMA200 $17.53 (current price $19.55 is above) · 💰 Market Cap $37.5B
- KVUE shows decent technicals supported by positive sentiment.

💎 Quality (Q): 52/60
- 🏦 Low drawdown (12.0% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 47% (>20%); ROE 15% (>15%); Low LT D/E 0.72 (<1.0).
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Kenvue raises quarterly dividend by 1.2% to $0.21 per share — Investing.com.
🤖 Kenvue’s dividend increase signals confidence in cash generation and shareholder returns, which is mildly supportive for the stock. The move is modest, so the impact is likely limited rather than transformative.
🍭 Bonus (B): 0/10 — Perfumes & Cosmetics

🏢 What they do: Taboola is an advertising technology company that operates a two-sided platform connecting advertisers with audiences across publisher websites and digital properties on the open web, using machine learning to match ads and content recommendations with users .
- 🎯 Current $5.29 is 5% below 3yr high $5.58 · ⏳ SMA200 $4.07 (current price $5.29 is above) · 💰 Market Cap $1.5B
- TBLA passed all filters and shows favorable conditions.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 200% (>20%); Low LT D/E 0.08 (<1.0); PEG ratio 0.07 (<1.5).
📢 Sentiment (S): 5/10
- 🗞️ News sentiment is neutral (mixed coverage).
✅ Taboola stock hits 52-week high at 5.26 USD — Investing.com.
🤖 The piece highlights Taboola reaching a 52-week high and points to its prior quarter’s strong earnings beat and the planned Russell index inclusion. Those factors are supportive for sentiment, although the article is mostly a price-action recap.
❌ Taboola shares tumble 17% on earnings miss, weak guidance — Investing.com.
🤖 Taboola reported Q2 adjusted EPS of $0.01, below estimates, and revenue of $476.8 million, also below consensus. Management’s Q3 and full-year revenue guidance came in well below expectations, which pressured the stock.
⚪️ Taboola.com Ltd. (TBLA) Q2 Earnings Surpass Estimates — Zacks.
🤖 The article says Taboola beat EPS expectations with $0.14 per share, but revenue of $476.83 million missed estimates. The mixed earnings beat-and-miss makes the stock impact broadly neutral.
🍭 Bonus (B): 10/10 — Computer Programming & Data Processing (Technology sector)

🏢 What they do: Custom Truck One Source (CTOS) provides specialty trucks, heavy equipment, parts, tools, and related services for infrastructure industries such as electric utilities, telecommunications, and rail. The company’s business includes equipment rental, equipment sales, aftermarket parts, customization, maintenance, and repair services.
- 🎯 Current $11.02 is 8% below 3yr high $11.97 · ⏳ SMA200 $7.71 (current price $11.02 is above) · 💰 Market Cap $2.5B
- CTOS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 38/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 138% (>20%); PEG ratio 0.80 (<1.5).
⏰ Entry (E): 11/20
- 🔔 Strong above EMA21 (5.3%)
- 🔔 SMA20/SMA50 bullish crossover
- ⚠️ SMA20/SMA50 bearish crossover
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Custom Truck One Source stock jumps 7% on Q2 beat, raised guidance — Investing.com.
🤖 CTOS reported second-quarter EPS and revenue above estimates and raised full-year 2026 revenue and adjusted EBITDA guidance. The stronger results and higher outlook are constructive for the stock price.
✅ Custom Truck One Source posts earnings beat by $0.04, revenue topped estimates — Investing.com.
🤖 The company reported second-quarter EPS of $0.05 versus a $0.01 estimate and revenue of $563.4 million versus $509.7 million expected. Beating both key metrics is typically positive for shares.
✅ Why is Custom Truck One Source stock up today? — Investing.com.
🤖 This article explains that the stock rallied after CTOS delivered a significant earnings and revenue beat and raised full-year 2026 revenue guidance. The combination of an earnings surprise and improved outlook is positive for the stock.
🍭 Bonus (B): 0/10 — Equipment Rental & Leasing

🏢 What they do: Flywire Corporation is a global payments enablement and software company that helps businesses collect and reconcile payments, especially for complex, cross-border transactions. Its platform includes invoice-to-cash automation, payment collection, currency conversion, and ERP/accounting reconciliation for industries like education, healthcare, travel, and B2B.
- 🎯 Current $17.26 is 51% below 3yr high $35.05 · ⏳ SMA200 $14.15 (current price $17.26 is above) · 💰 Market Cap $2.1B
- FLYW shows decent technicals supported by positive sentiment.

💎 Quality (Q): 48/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 433% (>20%); Revenue growth 41% (>15%); Low LT D/E 0.02 (<1.0); PEG ratio 0.17 (<1.5).
⏰ Entry (E): 0/20
- 📈 RSI at 54 in healthy mid-range
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Flywire Reports Second Quarter 2026 Financial Results — Globe Newswire.
🤖 Flywire reported Q2 revenue of $167.7 million, up 27.2% year over year, and said it repurchased about 3.1 million shares. The company also raised its 2026 outlook, which is generally supportive for the stock.
✅ Flywire Q2 2026 slides: strong beat across metrics, AI drives leverage — Investing.com.
🤖 The article says Flywire beat across key operating metrics, with revenue and adjusted EBITDA both above guidance. It also notes that Flywire raised full-year 2026 outlook, a bullish signal for investors.
✅ Flywire Corp (FLYW) (Q2 2026) Earnings Call Highlights — Yahoo Finance.
🤖 This earnings recap highlights that Flywire beat revenue expectations and improved profitability metrics in Q2. The company’s stronger results and improved outlook are favorable for the share price.
🍭 Bonus (B): 0/10 — Business Services

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 Current $56.00 is 2% below 3yr high $57.10 · ⏳ SMA200 $45.74 (current price $56.00 is above) · 💰 Market Cap $14.2B
- EXEL passed all filters and shows favorable conditions.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (9.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 44% (>20%); ROE 43% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 📈 RSI at 55 in healthy mid-range
📢 Sentiment (S): 5/10
- 🗞️ News sentiment is neutral (mixed coverage).
✅ Exelixis, Inc. (EXEL) Hit a 52 Week High, Can the Run Continue? — Yahoo Finance.
🤖 The article says EXEL reached a new 52-week high of $57.57 and has been strong over the past month, which is a favorable price action signal for the stock. It does not report a negative catalyst, but it is more a momentum update than fundamental news.
❌ Exelixis (NASDAQ:EXEL) Cut to Strong Sell at Zacks Research — MarketBeat.
🤖 Zacks Research downgraded EXEL from hold to strong sell, which is a negative analyst signal for the stock. The same item also notes conflicting analyst actions from other firms, but the downgrade headline is the main market-relevant takeaway.
⚪️ Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026 — Yahoo Finance.
🤖 This is only an announcement of the upcoming earnings release and conference call, with no results, guidance, or analyst view yet. Per your instructions, it is not meaningful stock news beyond the scheduling notice, so it is neutral.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Vericel Corporation is a biopharmaceutical company that develops, manufactures, and markets advanced cell therapies and specialty biologics for sports medicine and severe burn care. Its main products include MACI for knee cartilage repair, Epicel for severe burns, and NexoBrid for eschar removal in burn treatment.
- 🎯 Current $46.34 is 25% below 3yr high $61.80 · ⏳ SMA200 $37.44 (current price $46.34 is above) · 💰 Market Cap $2.4B
- VCEL shows decent technicals supported by positive sentiment.

💎 Quality (Q): 48/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 500% (>20%); Revenue growth 22% (>15%); Low LT D/E 0.04 (<1.0); PEG ratio 0.19 (<1.5).
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Vericel Q2 2026 slides: record revenue, first profitable quarter — Investing.com.
🤖 Vericel reported record second-quarter revenue of $77.5 million, beat EPS and revenue estimates, and posted its first profitable second quarter. The stock rose after the release, and the results were paired with stronger cash generation and improved margins.
✅ Canaccord raises Vericel stock price target to $60 on Q2 beat — Investing.com.
🤖 Canaccord lifted its price target to $60 and kept a Buy rating after Vericel’s stronger-than-expected Q2 results. The note cited record revenue, profitability improvement, and a new $200 million share repurchase program, all supportive for the stock.
✅ Vericel reports second-quarter 2026 financial results and raises full-year revenue guidance — Yahoo Finance.
🤖 Vericel said Q2 revenue grew 22% to $77.5 million and also raised full-year 2026 revenue guidance to $330 million to $340 million. It additionally authorized a $200 million share repurchase program, which investors typically view as a positive capital-allocation signal.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Proto Labs, Inc. is a digital manufacturing company that provides rapid prototyping and on-demand production services for custom parts. It offers manufacturing methods such as CNC machining, injection molding, 3D printing, and sheet metal fabrication, with online quoting and design-for-manufacturability feedback to help customers move from prototype to production.
- 🎯 At/above 3yr high $88.40 (current $88.40) · ⏳ SMA200 $62.14 (current price $88.40 is above) · 💰 Market Cap $2.1B
- PRLB shows decent technicals supported by positive sentiment.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 106% (>20%); Low LT D/E 0.00 (<1.0); PEG ratio 0.67 (<1.5).
⏰ Entry (E): 13/20
- 🔔 Strong above EMA21 (13.5%)
- 🔔 Strong above EMA50 (16.7%)
- 🔔 SMA20/SMA50 bullish crossover
- 🔔 Fresh SMA50 breakout
- 📈 RSI at 69 showing strength
- ⚠️ SMA20/SMA50 bearish crossover
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Proto Labs (NYSE:PRLB) Hits New 12-Month High After Analyst Upgrade — MarketBeat.
🤖 Needham & Company upgraded PRLB from hold to buy and set an $87 price target, which is generally bullish for the stock. The article also notes the shares reached a new 52-week high.
✅ Proto Labs stock hits 52-week high at 83.19 USD — Investing.com.
🤖 The piece says PRLB hit a 52-week high and highlights strong recent price momentum. It also cites improved earnings and a higher outlook, which support a positive stock view.
✅ Proto Labs (PRLB) Issues Q3 2026 Earnings Guidance — MarketBeat.
🤖 Proto Labs guided Q3 EPS above analyst expectations and revenue roughly in line, following a quarter that beat estimates on both EPS and revenue. Raising or beating guidance is typically favorable for the stock.
🍭 Bonus (B): 0/10 — Fabricated Structural Metal

🏢 What they do: Steven Madden, Ltd. (SHOO) designs, sources, markets, and sells fashion-forward footwear, along with accessories and apparel. It sells products under its own brands and also licenses certain brands, distributing through retail stores, e-commerce, and wholesale channels.
- 🎯 Current $48.86 is 2% below 3yr high $49.70 · ⏳ SMA200 $39.84 (current price $48.86 is above) · 💰 Market Cap $3.6B
- SHOO shows decent technicals supported by positive sentiment.

💎 Quality (Q): 48/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 168% (>20%); Revenue growth 19% (>15%); Low LT D/E 0.13 (<1.0); PEG ratio 0.15 (<1.5).
⏰ Entry (E): 9/20
- 🔔 Strong above EMA21 (10.3%)
- 🔔 Strong above EMA50 (14.3%)
- 🔔 SMA20/SMA50 bullish crossover
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 68 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Steven Madden (NASDAQ:SHOO) Sets New 52-Week High — MarketBeat.
🤖 MarketBeat reported that SHOO hit a new 52-week high after the company’s recent earnings beat and upbeat guidance. The stock’s strength reflects favorable investor reaction to the quarter.
✅ Steven Madden shares rise after earnings beat, higher outlook — Seeking Alpha.
🤖 This article says SHOO rose after second-quarter results beat analysts’ expectations and management raised fiscal 2026 projections. Strong revenue growth and improved guidance are typically supportive for the stock.
✅ Steven Madden (SHOO) Q2 Earnings and Revenues Top Estimates — Yahoo Finance.
🤖 Yahoo Finance reported that SHOO delivered earnings and revenue above consensus estimates for the quarter ended June 2026. Beating expectations on both top and bottom lines is generally positive for the share price.
🍭 Bonus (B): 0/10 — Manufacturing

🏢 What they do: John Wiley & Sons, Inc. (Wiley) is a global research and learning company that publishes over 1,900 peer-reviewed scientific, technical, medical, and scholarly journals along with academic and professional books, encyclopedias, and digital content .
- 🎯 Current $54.68 is 2% below 3yr high $55.72 · ⏳ SMA200 $38.26 (current price $54.68 is above) · 💰 Market Cap $2.9B
- WLY shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (7.7% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 103% (>20%); ROE 26% (>15%); Low LT D/E 0.81 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (6.7%)
- 🔔 Strong above EMA50 (13.5%)
- 📈 RSI at 63 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ John Wiley & Sons B stock hits 52-week high at 54.49 USD — Investing.com.
🤖 The article is positive because it highlights a new 52-week high and strong one-year price performance, which reflects favorable market momentum for $WLY. It also cites a strong recent move in the share price.
✅ John Wiley & Sons (NYSE:WLYB) Sets New 12-Month High — MarketBeat.
🤖 This is positive for $WLY because it reports the stock reaching a new 52-week high. The article also references the company’s recent earnings beat and dividend payment, both supportive signals for investors.
⚪️ Dimensional Fund Advisors LP Boosts Stake in John Wiley & Sons Inc. (WLY) — MarketBeat.
🤖 This is mildly positive because it reports increased institutional ownership, which can signal investor confidence in $WLY. However, the article is mainly a holdings filing recap and does not provide a new operational catalyst for the stock.
🍭 Bonus (B): 0/10 — Book Publishing